Transfusion Related Acute Lung Injury (TRALI) Caused by Red Blood Cell Transfusion Involving Residual Plasma Anti-HLA Antibodies: A report on two Cases and General Considerations by Odent-Malaure, Hélène et al.
Transfusion related acute lung injury (TRALI) caused by red blood cell
transfusion involving residual plasma anti-HLA antibodies: A report on
two cases and general considerations
HE ´LE `NE ODENT-MALAURE
1, FABIENNE QUAINON
1, PASCALE RUYER-DUMONTIER
1,
SOIZICK DUCROZ
2, PHILIPPE VERDIER
2, EVELYNE VOITELLIER
3, MARIE-FRANC ¸ OISE
RAYNAL
3, PATRICIA FROMONT
4, JEAN-YVES MULLER
4, DANIELLE REBIBO
5,L E ´NA
ABSI
1, & OLIVIER GARRAUD
1
1Etablissement Franc ¸ais du Sang Auvergne, Loire, France,
2Centre Hospitalier de Montluc ¸on, Montluc ¸on, France,
3Centre
Hospitalier de Vichy, Vichy, France,
4Laboratoire d’Immunologie, CHU de Nantes, Nantes, France, and
5Etablissement
Franc ¸ais du Sang, Direction Me ´dicale et Scientiﬁque, Paris, France
Abstract
TRALI is considered a serious hazard among immune complications of blood transfusion and its occurrence is admitted to be
globally underestimated. Each type of blood product is likely to cause TRALI. We report here on two consecutive observations
of TRALI caused by red blood cell concentrates, in which anti-HLA class I and class II antibodies resulting from post-
gravitational allo-immunization were evidenced in donors. HLA class I and II antigenic community between recipients and
donors’ husbands were found and strong reacting IgG antibodies directed at several of those common antigens were detected
in the donors’ serum. Both donors had more than 3 pregnancies, raising the issue of blood donor selection or of plasma
reduction for cellular products.
Introduction
There are currently no alternatives to blood transfu-
sion (BT). Many attempts have been made, which
were primarily motivated by: (i) a desire to secure
supplies in case of catastrophic circumstances or for
use in the battle ﬁeld and (ii) the desire to reduce or
eliminate the occurrence ofinfectious consequences of
blood transfusion, such as those encountered in the
early (human immunodeﬁciency virus (HIV)) and late
(hepatitis C virus (HCV)) 1980s. Although, some
risks regarding blood transfusion still exist due to
possible emerging diseases, which may be transmis-
sible via transfusion, the overall risk from transfusion
transmitted (TT) infections is currently very low.
Incidental exposure to major TT viruses, such as HIV
and HCV, are very rare. However, further measures
can be taken for hepatitis B virus (HBV), cytomega-
lovirus (CMV), erythrovirus (parvovirus) B19, para-
sites and bacteria (the most current TT infection
source) (Koistinen 2004). However, the immunologi-
cal risks linked to bone marrow transfusion (BMT)
remain quite high, although these are diverse in terms
of causes and consequences (Goodnough 2003).
Blood or blood product substitutes have been
developed, but have consistently resulted in an
immunogenic response, such as the host production of
neutralizing antibodies to anti-hemophiliac
recombinant factor VIII (Key 2004). Among the
immunological risks presented by transfusion of labile
blood products,such as packedred blood cells (PRBC),
fresh frozen therapeutic plasma and platelet concen-
trates,istransfusionrelatedacutelunginjury(TRALI),a
transfusion-associated acute respiratory distress syn-
drome (ARDS). It is now commonly thought that
TRALI is largely underestimated both in frequency
and in diagnosis (according to the “iceberg theory” of
the clinical forms) (Boshkov 2004). TRALI may
be confused with other ARDS, such as transfusion
associated circulatory overload (TACO), acute
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possible complications of BT associated with hypervo-
lemia or overload. Other causes of ARDS that are
observed following transfusion are anaphylactic allergy,
severe bacterial infection and septic shock. Except for
anaphylactic allergy, these syndromes are not caused by
an immunological response (Popovsky et al. 1983).
The recognition of TRALI necessitated the gener-
ation of a consensus description and a commitment to
understand the physiopathology of the syndrome; the
committee’s consensuses have clariﬁed clinical, radio-
logical and biological criteria describing TRALI
(Goldman et al. 2005; Toy et al. 2005). TRALI
presents with pulmonary endothelial lesions not
associated with any other cause of ARDS or
cardiogenic shock. The physiopathology of TRALI
is complex and not clearly understood. TRALI
presents as an accumulation of polynuclear neutro-
phils locally activated by antibodies in the pulmonary
endothelium. The antibodies seem to activate the
neutrophils, monocytes, and/or endothelial cells.
Cytokines and toxic cellular products of platelet lipid
origin may amplify these acute inﬂammatory
responses. However, labile blood products other
than platelets can also cause TRALI. The patient
may also have a clinical predisposition for TRALI. In
any case, it seems that there is an antigen (Ag)-
antibody reactivity between the blood donor’s plasma
and the recipient’s cells, or possibly vice-versa in some
cases. Even a residual amount of antibody-containing
plasma from the donor, which we describe here, can
be responsible for TRALI (Popovsky 2000; Kopko
2004a,b; Nishimura et al. 2004; Muller 2005).
The pathophysiology of TRALI appears to result
from (i) the transfer of pre-existing antibodies from
the blood donor to the recipient, (ii) a clinical
predisposition or (iii) the involvement of metabolic
factors originating from the blood product (Popovsky
et al. 1983; Popovsky and Moore 1985; Popovsky and
Haley 2001; Boshkov and Silliman 2004).
The antibodies are principally derived from the
donor plasma and are primarily of the IgG isotype.
The antibodies recognize targets on the recipient’s
white blood cells (WBCs), including HLA class I or II,
granulocyte antigen (commonly referred to as anti-
HNA antibodies), and the CD16 surface antigen.
The activated WBC contribute to lung epithelium
damage (Kopko and Popovsky 2004). Pregnancies are
thought to be the origin of such allo-antibodies.
Individuals with a history of transfusion, as well as
graft or transplantation, cannot donate blood.
TRALI occurrences could be largely underesti-
mated. It is currently estimated that one in ﬁve
described TRALI incidents has a fatal outcome
(Wallism 2003). We present here two consecutive
occurrences of TRALI, which were observed after BT
of PRBC and mediated by traces of anti-HLA
antibodies present in the residual plasma.
Patients observations and laboratory
investigations
The Auvergne-Loire regional haemovigilance depart-
ment of the E ´tablissement Franc ¸ais du Sang over the
last 4 years has identiﬁed three cases of TRALI
diagnosed according to the criteria established by
Popovsky and Moore (1985). Approximately 330,000
blood products were distributed during this period.
The ﬁrst case of TRALI was reported and involved
transfused plasma products (Odent-Malaure 2001;
Fromont et al. 2002; Odent-Malaure 2004). The two
remaining cases are presented here and involved
transfused PRBC. The two cases will be referred to as
case 1 and 2.
Case 1
A78year-oldmalepresentedwithmyelodysplasiainJune
2003andreceivedonePRBC(ABO,RH1,2–5andRH-
KEL1 and two compatible). There were no irregular
antibodies detected by indirect antiglobulin test (IAT)
immediatelypriortotransfusion.Thetransfusion-related
accidentoccurredimmediately,afterthreequartersofthe
transfusion, and was diagnosed as TRALI based on
clinicalandradiologicalsymptoms;thepatientdeveloped
an acute dyspnea with bilateral crackles during lung
auscultation,chestX-rayexaminationsuggestedadiffuse
interstitial pulmonary edema, and the diagnosis of acute
respiratory distress was conﬁrmed by laboratory tests.
Resuscitation measures were taken and the patient
recovered from this episode within 24h. The PRBC was
7dayoldandhadbeenpreparedfromblooddonatedbya
36 year-old female that had given birth to 4 children
(5 total pregnancies). Donors should not have been
previously transfused according to national French
regulations. A standard micro-lymphocytotoxicity tech-
nique (MLCT) determined that the donor’s serum
contained strongly reacting anti-HLA class I and anti-
HLA class II IgG antibodies (93% of the panel cellswere
labeled). (Lazezari et al. 1976). It was difﬁcult to identify
the antigens using either classical MLCT or a sensitive
LATw (Lambda Antigen Tray- class I, class II, One-
Lambda,CanogaPark,CA,USA)technique.Welooked
for shared HLA speciﬁcities between the recipient’s and
the donor’s (patient’s husband) peripheral blood
mononuclear cells. We identiﬁed four shared Ag, HLA
A9, B12, DR7 and DR53, using micro-lymphocytotoxi-
city, serology and molecular biology techniques, which
have been validated by the European Foundation for
Immunogenetics (Daniels 2004; Turner 2004).
PCR sequence speciﬁc primer genotyping was
performed using the Dynal (Biotech ASA, Oslo,
Norway) kits for HLA class I Ag and One Lamba kits
for the HLA class II Ag. Anti-HLA B12 (B44 þ B45)
and DR53 were identiﬁed in the donor’s serum by the
LATw technique. The serum IgG antibody reacted
strongly and remained granulo-agglutinating at a titer
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granulocyte antibodies was suspected because the
donor’s serum proved capable of reacting, both in ﬂow
cytometry and in the Lazezari’s microagglutination
technique (GAT), with HNA1a, HNA1b, HNA1c,
and HNA2a granulocytes (Lazezari et al. 1976; Veys
et al. 1989; Bux et al. 1993). Monoclonal antibody
(mAb)-speciﬁc immobilization of granulocyte anti-
gens (MAIGA) test positivity indicated the presence
of speciﬁc anti-granulocyte antibody because the
donor serum gave a weak positive reaction with mAb
DJ-130c (Dakocytomation, Trappes, France), but not
mAb 3G8 (Beckton Dickinson, Le Pont-de-Claix,
France). MAb DJ-130c occasionally gave unexplained
positive reactions with HLA class I antibodies in the
absence of any anti-granulocyte antibody (JYM’s
unpublished observations). Thus, the involvement of
an anti-HNA antibody was not considered. The
observed granulocyte reactivity was determined as an
anti-HLA class I antibody. Case 1 is summarized in
Table I.
Case 2
A 70 year-old female underwent surgery for colonic
carcinoma and received two consecutive PRBC to
compensate for anemia in March 2004. This
unmarried patient did not report any previous
pregnancy and had not been previously transfused or
allografted. No irregular antibodies were detected by
pre-transfusion IAT. Two ABO, RH1, 2–5, and RH-
KEL1 and 2 compatible leukocyte-reduced PRBC
were transfused. The ﬁrst one was prepared from a 30
year-old female donor reporting 3 children (2
pregnancies of which one was gemellar). The second
PRBC was prepared from a 42 year-old female
reporting 4 children (5 pregnancies in total). These
PRBC were stored for 32 and 39 days prior to
infusion, respectively. The reaction occurred 2h after
the end of the second PRBC infusion. It
was determined as TRALI based on clinical and
radiological signs: the patient reported chills and acute
dyspnea developed. Examination showed diffuse
bilateral crackles without wheezing. A radiograph of
the chest revealed diffuse, bilateral air-space con-
solidation, which was consistent with the presence of
pulmonary edema. The diagnosis of acute respiratory
distress was conﬁrmed by laboratory tests. The patient
was transferred to an intensive care unit and recovered
from this episode within 48h.
The recipient’s serum had neither anti-HLA class I
nor II antibodies prior to transfusion, which was
determined by retesting of the pre-transfusion blood
sample that was kept frozen. Antibodies were found
only in the second donor’s serum. This serum reacted
with the recipient’s and her current husband’s T- and
B-lymphocytes, which were prepared after indirect
magnetic separation of ﬁcoll isolated PBMC
Table I. Case report 1 on the occurrence of TRALI after transfusion of packed red blood cells.
Blood donor Immunizer Blood receiver
Age 36 yo 78 yo
Gender Female M (Spouse) Male
Medical history
Indication of transfusion Myelodysplasia (anemia)
Occurrence of the adverse reaction During (3/4) the transfusion*
Outcome Favorable within 24h
Immunization
Transfusion None Previously transfused (4 times in two
years)
Pregnancies
No. of pregnancies 5 (4 children) NA
Serology
Anti-HLA Abs
† Strongly reacting anti-class I and II
Abs (anti-A29, B44 þ 45 (12) DR7
NT Not tested prior to the transfusion
None immediately after transfusion
Anti-HNA Abs
‡ Suspected, not conﬁrmed NT None
HLA-typing (a)
HLA A 25 (10), 30 (19) 24 (9), 29 (19) 23 (9), 24 (9)
HLA B 18, – 44 (12), 45 (12) 8, 44 (12)
HLA DR 2, 3 7, 10 0103, 7
HLA DQ 1, 2 1, 2 1, 2
Shared Ags – (A9), B12, DR7,
Ab production to (A29), B12, DR7 – –
*The ﬁrst PRBC was transfused. This pack was issued from a donation from a 36 year-old (yo) female reporting 3 pregnancies. This female
donor tested negative for anti-HLA and HNA plasma antibodies.
†Testing by standard Micro-Lymphocytotoxicity (MLCT) and by ELISA (LATw; Lambda Antigen Tray-class I and II, One Lambda,
Canoga Park, CA, USA). For MLCT, T- and B-cells were prepared by indirect magnetic separation of ﬁcoll-isolated PBMCs23 (Dynabeads,
Dynal, Roskilde, Denmark).
‡Testing by the MAIGA technique, using a panel of anti-CD16 and -CD177 monoclonal antibodies (Abs) (Bux et al.).
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HLA-A29, -B17, -B12 (B44 þ B45) and -DR7
allo-antibodies were identiﬁed in this donor’s serum.
The donor’s husband, typed for HLA class I and II,
was A2, A29, B44, B51, DR7, DQ2 and DQ3. The
recipient typed positive for DR7 class II Ags and for
B45 class I Ag, which along with B44 are the two main
serologic splits of B12. B12 Ags are known to strongly
cross-react in terms of antigenicity and immunogeni-
city. This anti-class I speciﬁcity could account for
the granulocyte reactivity observed with this serum
using GAT and ﬂow cytometry. MAIGA negativity
using anti-CD16 and anti-CD177 mAbs suggested
there was no additional speciﬁc anti-granulocyte
reactivity. Case 2 is summarized in Table II.
Discussion
These two consecutive cases underscore the role of
PRBC in TRALI in addition to the more commonly
reported occurrences involving platelets and plasma.
TRALI has been suspected or conﬁrmed in over 10%
of transfusion-related deaths in each of the last 4 years,
and in over 15% of these cases over the last 2 years in
the U.S. (America’s Blood Center 2004). According
to a consensus at a Canadian conference held earlier in
2004, the estimate for TRALI occurrence ranges from
1 in 5000 to 1 in 100,000 for all transfusion
components. However, this depends on what is
actually deﬁned as TRALI (Mariani 2003). In general,
the occurrence of TRALI has been largely under-
estimated and the relevant physiopathology is still not
understood. Furthermore, data establishing a deﬁni-
tive link between gender and anti-HLA antibodies, a
major cause of TRALI is lacking. Fifteen cases of
TRALI were recorded and fully documented in 2003
according to the French Haemovigilance Network at
the Etablissement Franc ¸ais du Sang. Three were
associated with fatalities. Nine, which included all
3 fatal cases, were associated with platelet concen-
trates (incidence: 1/25,000 products), 2 were associ-
ated with therapeutic plasma (incidence: 1/130,000)
and 4 were associated with PRBC (incidence:
1/500,000) (Rebibo et al. 2004). These frequencies
are comparable to those from the most organized and
centralized haemovigilance systems, such as the
British (SHOT) and the Canadian systems. The
estimated mortality rate ranges from 10 to 20%,
provided that the case is identiﬁed. Thus, it is likely
that TRALI is more important than initially thought.
We report here two occurrences of clinically docu-
mented TRALI that resulted from PRBC transfusion,
Table II. Case report 2 on the occurrence of TRALI after transfusion of packed red blood cells.
Blood donor Immunizer Blood receiver
Age 30 yo 72 yo
Gender Female M (Spouse) Female
Medical history
Indication of transfusion Colonic carcinoma necessitating surgery
(anemia)
Occurrence of the adverse
reaction
Two h after the end of the second PRBC*
Outcome Favorable within 48h
Immunization
Transfusion None 1st occurrence
Pregnancies
# of pregnancies 3 (1 gemellar) None
Serology
Anti-HLA Abs
† Anti-A29, B17, B44 þ B45 (12), DR7† NT None prior to the transfusion
None after transfusion (conﬁrmed)
Anti-HNA Abs
‡ None NT NT
HLA-typing (a)
HLA A 3, – 2, 29 (19) 3, 26 (10)
HLA B 7, – 44 (12), 51 (5) 8, 45 (12)
HLA DR 2, 13 (6) 7, – 3, 7
HLA DQ 1, – 2, 3 2, –
Shared Ags – B44/45 (12), DR7
Ab production (A 29), B44/45 (12),
DR7
––
*The ﬁrst PRBC was transfused. This pack was issued from a donation from a 30 year-old (yo) female reporting 3 pregnancies. This female
donor tested negative for anti-HLA and HNA plasma antibodies.
†Testing by standard Micro-Lymphocytotoxicity (MLCT) and by ELISA (LATw;Lambda Antigen Tray-class I and II, One Lambda, Canoga
Park, CA, USA). For MLCT, T and B cells were prepared by indirect magnetic separation of ﬁcoll-isolated PBMCs (Dynabeads, Dynal,
Roskilde, Denmark).
‡Testing by the MAIGA technique, using a panel of anti-CD16 and -CD177 monoclonal antibodies (Abs) (Bux et al.).
H. Odent-Malaure et al. 246but ended with favorable outcomes. The clinical details
have been presented elsewhere (Odent-Malaure 2004).
Tables I and II provide the biological details and
procedures. It is worth noting that in the two cases
reported here the PRBC bags came from two different
manufacturers. The residual volumes of plasma, shown
to contain anti-HLA antibodies, were 32 and 39ml and
containedapproximately50gfreesolubleproteinperliter
of plasma. Leuko-reduction was performed during the
processing to leave less than 10
6 leukocytes per unit in
accordance to the national French requirements.
Residual leukocytes were #9a n d#7 £ 10
4 per unit
after preparation, but it is unlikely that the leukocytes
persisted after a 37 day storage at 48C( C a s e2 ) .O n e
PRBCsamplewas7dayold(Case1),whiletheotherwas
37 day old (Case 2), which likely excludes the role of
blood product aging in PRBC associated TRALI
(Popovsky 2000). The two adverse reactions occurred
using blood products donated by multiparous females.
The cases involved the development of strong allo-
antibodies (IgG) against HLA class I and II Ags, which
werepresentonthesomaticcellsofthedonors’husbands
and were shared by the respective recipients. Interest-
ingly, HLA typing ofthe donors’ husbands proved useful
in identifying the speciﬁcity involved in TRALI. Such
allo-immunization is very likely to be related to
pregnancies and the donor’s husband’s HLA typing
may be useful for identifying the speciﬁcity involved in
TRALI as illustrated by Case 1 (Popovsky and
Davenport 2001). It is noteworthy that in each case the
outcome for the patient was favorable. Based on these
observations, and those in the general literature, no
conclusions regarding the selection of blood donors can
be made. Systematic exclusion of multiparous donors
would lead to a dramatic shortage of cellular blood
products (Muller et al. 1981). Large scale testing of
multiparous female donor serum for anti-HLA anti-
bodies after each pregnancy may be possible, but after
which pregnancy to begin such testing remains to be
determined. Indeed, it is estimated that among the
332,240 whole blood donations 16,500 PRBC were
preparedand distributedfrom donationsbyfemaleswith
greater than 3 children or pregnancies during the
survey period in the Auvergne-Loire region at Etablisse-
mentFranc ¸aisduSang.Implementationofcost-effective
techniques leading to an almost complete depletion
of residual plasma in PRBC might be a desirable
alternative to exclusion without or after testing of
female donors having had a critical number of
pregnancies.
Despite great progress with regard to the reduction
in pathogen-induced complications of transfusion, a
risk of immunological complications resulting from
the infusion of trace amounts of adverse antibodies
remains. The selection of donors merits special
focus, especially for blood recipients with sensitive
medical, such as multiple transfusions, or surgical
histories.
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